文献速递前列腺癌

基于风险的前列腺特异性抗原监测减少根治性前列腺切除术后随访负担

Risk-based Prostate-specific Antigen Monitoring Reduces Follow-up Burden After Radical Prostatectomy.
PubMed 文献 · Eur Urol Oncol · 2025-05-05

该研究基于荷兰全国癌症登记2015-2016年1043例接受根治性前列腺切除术且术后6周内PSA不可测的局限性前列腺癌患者,依据PSA、pT、pN、ISUP分级和切缘状态构建三个生化复发风险组,提出风险适配的5年PSA监测方案。新方案较EAU推荐方案减少18%的咨询次数,但延迟3%的BCR检测。

要点

  • 低危组5年需4次PSA检测,中危组8次,高危组10次。
  • 新方案较EAU方案减少18%的随访咨询,延迟3%的BCR检测。
  • 风险分组基于PSA、pT、pN、ISUP分级和切缘状态。

核心结论

  • 风险适配的PSA监测方案可减少不必要的PSA检测,尤其低危患者,不损害BCR检出率。

研究设计与样本

  • 基于荷兰全国癌症登记2015-2016年1043例接受根治性前列腺切除术且术后6周内PSA不可测的局限性前列腺癌患者的回顾性队列研究。

主要发现

  • 43%为低危(BCR率15%),42%为中危(BCR率36%),15%为高危(BCR率72%)。
  • 总体5年无BCR生存率为62%(95%CI 58-66)。
  • 新方案5年内低危需4次、中危需8次、高危需10次咨询,较EAU方案减少18%咨询,延迟3%的BCR检测。

关键数值与推荐

  • BCR定义为PSA≥0.1 ng/ml。
  • BCR显著预测因素包括诊断时PSA、pT分期、pN分期、ISUP分级分组和手术切缘阳性。

临床怎么用

  • 可根据风险分组调整根治性前列腺切除术后PSA监测频率,低危患者减少检测次数。

局限性

  • 可能存在信息性删失导致的偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU)-recommended follow-up schedule after radical prostatectomy (RP)-biannual prostate-specific antigen (PSA) testing for 3 yr, followed by annual testing-does not take into account variations in biochemical recurrence (BCR) risk. Therefore, we propose an optimised, risk-adapted PSA monitoring schedule for the first 5 yr after RP, stratifying patients into BCR-based risk groups, to reduce unnecessary PSA testing without compromising BCR detection rates. METHODS: Men were diagnosed with localised prostate cancer in 2015-2016, who underwent primary RP, with undetectable PSA levels <6 wk after RP, as identified in the nationwide Netherlands Cancer Registry. The outcome measures included BCR-free survival (BCR defined as PSA ≥0.1 ng/ml). Cox proportional hazards models were used to identify three risk groups; Kaplan-Meier curves illustrated BCR-free survival rates. The average BCR risk per PSA follow-up consultation in the current EAU schedule was used as a threshold to determine consultations needed in the revised risk-based schedule. KEY FINDINGS AND LIMITATIONS: In total, 1043 patients were included in the study. Significant predictors for BCR included PSA at diagnosis, pT stage, pN stage, pathological International Society of Urological Pathology grade group, and positive surgical margins. Stratification (based on hazard ratio) resulted in 43% low-risk (15% BCR), 42% intermediate-risk (36% BCR), and 15% high-risk (72% BCR) patients. The overall 5-yr BCR-free survival rate was 62% (95% confidence interval 58-66). Low-risk patients required four, intermediate-risk patients required eight, and high-risk patients required ten consultations in the revised schedule over the first 5 yr, reducing 18% of consultations compared with the EAU schedule, with 3% delayed BCR detection. Study limitations include a potential bias due to informative censoring. CONCLUSIONS AND CLINICAL IMPLICATIONS: This optimised risk-adapted PSA monitoring schedule following RP reduced the number of unnecessary PSA tests, particularly in low-risk patients, without compromising BCR detection rates.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Paulino Pereira LJ, van den Bergh RCN, Sedelaar MJPM, et al. Risk-based Prostate-specific Antigen Monitoring Reduces Follow-up Burden After Radical Prostatectomy. Eur Urol Oncol. 2025. PMID: 40328569. doi:10.1016/j.euo.2025.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。